Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

App-Based Digital Therapeutics Integrating Continuous Glucose Monitoring for Glycemic Control in Type 2 Diabetes: Prospective Observational Cohort Study.

JMIR diabetes·2026
Same author

Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer.

European urology open science·2026
Same author

An endodermal subpopulation generates neural and mesodermal fates in the posterior chick embryo.

bioRxiv : the preprint server for biology·2026
Same author

Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules.

Clinical genitourinary cancer·2026
Same author

Radiochemistry and comparative in vitro assessment of PSMA-617 labeled with lead-212 (<sup>212</sup>Pb), actinium-225 (<sup>225</sup>Ac), and lutetium-177 (<sup>177</sup>Lu).

EJNMMI radiopharmacy and chemistry·2026
Same author

Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: Jul 5, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K

Bladder-Preserving Trimodality Therapy With Capecitabine.

Connor Lynch1, Randy F Sweis2, Parth Modi3

  • 1Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL.

Clinical Genitourinary Cancer
|January 16, 2024
PubMed
Summary

Trimodality therapy with transurethral resection of bladder tumor (TURBT) and concurrent capecitabine shows high bladder control rates. This bladder-preserving approach offers effective cancer treatment with low toxicity for muscle-invasive bladder cancer patients.

Keywords:
Bladder cancerChemoradiation therapyRadiation therapy

More Related Videos

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.8K
Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

4.7K

Related Experiment Videos

Last Updated: Jul 5, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.8K
Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

4.7K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Medical Oncology

Background:

  • Muscle-invasive bladder cancer (MIBC) poses treatment challenges for patients unfit for radical cystectomy or standard chemoradiotherapy.
  • There is a need for less-intense chemotherapy regimens in bladder-preserving strategies for MIBC.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of trimodality therapy (maximal transurethral resection of bladder tumor [TURBT] + radiotherapy) using single-agent concurrent capecitabine in MIBC patients.
  • To assess bladder control, survival outcomes, and toxicity profiles of this bladder-sparing treatment approach.

Main Methods:

  • Patients ineligible for radical cystectomy or standard chemoradiotherapy underwent maximal TURBT followed by concurrent capecitabine and radiotherapy.
  • Toxicity was monitored prospectively, and survival outcomes (progression-free, cancer-specific, distant metastasis-free, bladder recurrence-free) were estimated using Kaplan-Meier methods.

Main Results:

  • A complete response rate of 93% was observed in the bladder and pelvis among 27 patients treated between 2013-2023.
  • Two-year survival estimates included 81% progression-free, 65% cancer-specific, 91% distant metastasis-free, and 92% bladder recurrence-free survival.
  • The treatment demonstrated a low toxicity profile, with 7 grade 3 acute hematologic/metabolic events and no other grade 3+ toxicities.

Conclusions:

  • Maximal TURBT combined with concurrent capecitabine and radiotherapy is an effective bladder-preserving option for MIBC.
  • This trimodality regimen achieves high rates of bladder control and exhibits a favorable toxicity profile, making it suitable for select patient populations.